American Journal of Tropical Medicine and Hygiene
Volume 102, Issue 6, June 2020
oa Ivermectin and COVID-19: Keeping Rigor in Times of Urgency
Carlos Chaccour, Felix Hammann, Santiago Ramón-García and N. Regina Rabinovich
… The discovery of ivermectin’s activity against SARS-CoV-2 gives reason for hope, but off-label and compassionate use requires careful risk–benefit considerations,27 especially in critically ill patients. A path to consider is evaluation first of impacts on virologic outcomes in uncomplicated, low-risk patients early in the course of the disease. Well-conducted clinical trials informed by robust pharmacokinetic models should be considered to validate the impact before the use of ivermectin to treat SARS-CoV-2 is implemented.